Catherine M. Engelbert
Director · Royalty Pharma plc
Individual
- 2026
- Jun 8, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Catherine M. Engelbert files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Terrance P. Coyne - $33.61M in RPRX purchases and sales in the last 12 months
- Christopher Hite - $27.36M in RPRX purchases and sales in the last 12 months
- Christopher J. Kempczinski - $17.47M in MCD purchases and sales in the last 12 months
- George W. Lloyd - $9.57M in RPRX purchases and sales in the last 12 months
- Marshall Urist - $7.01M in RPRX purchases and sales in the last 12 months
- Joseph M. Erlinger - $6.21M in MCD purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Catherine M. Engelbert?
Catherine M. Engelbert is a corporate insider, tracked as Director of Royalty Pharma plc (RPRX). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Catherine M. Engelbert last file a Form 4?
The most recent primary Form 4 on record is dated 8 June 2026, one of 2 filings going back to 2026.
